

Antimicrobial activity and *in silico* ADME prediction of synthesised 8-hydroxyquinoline *azo* compounds against some ESKAPE human pathogens and *Mycobacterium smegmatis*.

Abstract

Introduction: Antimicrobial resistance has increasingly been a global health concern over the past decades and that has necessitated the quest to increase the pool of antibiotics. **Methods:** Five (5) *azo* compounds were synthesised by diazotization and coupling procedures with yields of 60 – 92%. They were characterized by melting point determination, Ultra-Violet Visible, and Infra-red spectroscopy. High-throughput spot culture growth inhibition (HT-SPOTi) antimicrobial assay was used to evaluate the compounds. Computational studies was also employed to predict some pharmacokinetic properties of the *azo* compounds **Results:** From the *in silico* studies, none of the compounds violated Lipinski's rule and therefore, have the potential to be developed into an oral drug. They also showed Total Polar Surface Area (TPSA) values $< 140 \text{ \AA}^2$ (74.91 – 100.98 \AA^2) and percentage absorption of 74 – 83 %. They were placed in category III of acute oral drugs. From the high-throughput spot culture growth inhibition antimicrobial assay, all the compounds possessed inhibitory activity against the ESKAPE human pathogens and *Mycobacterium smegmatis*, with MICs range of $3.9 \geq 500 \text{ \mu g/mL}$. Except for 4e which showed liver toxicity, all the compounds demonstrated mutagenic and hepatotoxic tendencies. The modulatory

assay of the *azo* compounds revealed that 4c and 4e modulated the antimicrobial activity of ciprofloxacin against *Pseudomonas aeruginosa* and *Staphylococcus aureus*. 4c and 4e also modulated the antimicrobial activity of rifampicin against *Mycobacterium smegmatis*. Exploiting the ability of 4c and 4e to act by a mode of action revealed that they have biofilm formation inhibitory potential. **Conclusion:** Compounds 4c and 4e exhibited the best antimicrobial activity in terms of resistant modulation and biofilm inhibition against *Pseudomonas aeruginosa*, *Staphylococcus aureus* and *Mycobacterium smegmatis*.

Keywords

azo compounds, antimicrobial, biofilm inhibition, resistance modulation, efflux pump.

1.0 Introduction

Reports from the **World Health Organisation (2020)** indicate that pathogens that cause infectious diseases, which are the third most notable cause of mortality worldwide [1, 2]. Infectious diseases load is higher in developing countries, due to emergence of multidrug-resistant (MDR) pathogens by irrational behaviour of using antimicrobials [3, 4]. Gram-negative bacteria are liable to produce more MDR phenotypes and are responsible for causing more serious illness especially in immuno-compromised hosts; as compared to Gram-positive pathogens.

[5]. The highly prevalent MDR bacteria such as, *Pseudomonas sp.*, *Acinetobacter sp.*, *Staphylococcus sp.*, and *Mycobacterium sp.* are the major contributors to nosocomial and community-acquired infections posing critical health risks globally especially in Sub-Saharan Africa [6,7]. Fungal pathogens are also shown to develop resistance against routinely prescribed antifungal drugs, such as amphotericin B, fluconazole, and penicillins [8]. This is especially dangerous considering that fungal pathogen *Candida sp.* and bacteria are responsible for 75 % of all microbial infections [9]. The situation has been worsened by the development of extensively multi-drug resistant strains, including fluoroquinolones, of *Mycobacterium tuberculosis* [10, 11]. Laboratory evidence has shown that the presence of efflux pumps and biofilm formation in *Mycobacterium sp.*, *Pseudomonas aeruginosa*, *Escherichia coli*, and *Candida albicans* has contributed to the increasing resistance against most antibiotics [11]. It is also a fact that biofilms are responsible for 65 % of all bacterial infections which has contributed to increased antimicrobial resistance [11]. Moreover, most of the concerns in the treatment of nosocomial infections are with the ESKAPE pathogens (*Enterococcus faecium*, *Staphylococcus aureus*, *Klebsiella pneumoniae*, *Acinetobacter baumannii*, *Pseudomonas aeruginosa*, and *Enterobacter* species) [11]. Their infections pose a worrisome burden on the health sector, since the treatment with new / novel antibiotics eventually increase the expense of patient care. Therefore, understanding of the mechanisms of antibiotics resistance developed by pathogens, would help developing the novel antimicrobial agents [12].

The global antibiotics pipeline has been running dry, as a result of the surge in resistance, coupled with a decline in the number of new antibiotics being approved and reaching the market or the patient's bedside [13]. For instance,

the production of only two novel classes of antibiotics in the last five decades indicates that it may be a challenging task to produce an adequate set of compounds to boost modern drug discovery programs in the years to come [14]. Consequently, it is important to advance and design new antibiotic therapeutics to add up in the antibiotic stewardship programs, along with existing drug therapy, help clinicians to bring the better patient outcomes [15].

Azo dyes are suitable candidates to achieve this objective since they have been shown to be an important class of antimicrobial agents with versatile applications [16, 17]. It has been established that the inclusion of a suitable heterocyclic moiety increases the activity of the azo linkage [18]. Furthermore, the introduction of nitrogen containing heterocyclic compounds such as, quinoline, pyridine, thiadiazole, and triazole, confer the significant antimicrobial activities including anticancer, anti-inflammatory, and anti-mycotic activities [19]. Their synthetic route follows the diazotization of primary aromatic amines and an electron-rich moiety (coupling reagents) which mimics the principle of molecular hybridization [20, 21] (**Scheme 1**). Also, recent drug discovery strategies involve the development of novel chemical moieties by employing pharmacophore hybridization: a process of linking two biologically active groups together by a covalent bond [22, 23]. The selection criteria for molecular hybridization is usually based on their expected or practical pharmacological activities [23]. In the prospects of the hitherto evidence, and for the contribution to the research towards the development of pharmacophore hybrids as potential antimicrobial compounds, authors chose to chemically construct a library of novel molecular hybrids using 8 hydroxyquinoline as a scaffold, under suitable experimental reaction conditions, and access the antimicrobial properties.

2.0 Materials and Methods

2.1 Bacterial strains

Standard reference strains of Gram-negative pathogens, including, *Escherichia coli* (ATCC 25922), *Pseudomonas aeruginosa* (ATCC 27853), *Proteus mirabilis* (clinical strain), *Klebsiella pneumonia* (clinical strain), *Salmonella*

typhi (clinical strain), and gram-positive pathogens, including, *Staphylococcus aureus* (ATCC 25923), *Enterococcus faecalis* (ATCC 29212) were used for the antimicrobial study. *Mycobacterium smegmatis* mc² 155, an acid-fast mycobacterium, was also used in this study. The test organisms were all obtained from the cell culture laboratory, Department of Pharmacology, Kwame Nkrumah University of Science and Technology (KNUST), Kumasi, Ghana.

Glycerol stocks of the pathogens stored at -80 °C in a freezer, were removed, thawed, and cultured either on nutrient agar slants for most of the bacteria, or Middlebrook 7H10 agar for *Mycobacterium smegmatis*.

2.2 Culture Media and Reference Antibiotics

Nutrient Agar and Broth, as well as Middlebrook 7H10 Agar and Middlebrook 7H9 Broth, were purchased from Oxoid Limited, (Basingstoke, United Kingdom). Ciprofloxacin and Rifampicin were obtained from Sigma Aldrich™ (Michigan, USA).

2.3 Chemicals, Reagents and Instrumentation

The reactants and solvents were all obtained commercially from Fisher Scientific™ (United Kingdom). The progress of each synthetic reaction was monitored using thin-layer chromatography (TLC), on a pre-coated silica gel plate (Merck F254) and visualized with UV light (254 nm and 357 nm) or iodine vapour where necessary. The synthesised compounds were purified by recrystallization using suitable solvents. The samples were run neat to obtain their infra-red (IR) spectra, in the range 400 – 4000 cm⁻¹ on a Bruker FTIR

spectrophotometer (Bruker FTIR 94133). The ultraviolet-visible (UV-Vis) spectra were measured on a UV-Vis spectrophotometer (Jenway, U.K/7315), at 200 – 800 nm with methanol as blank. The melting point of the synthesised compounds was obtained by using one end or open capillary tubes on a Stuart melting point apparatus (England) and are uncorrected.

2.4 Synthesis, and Characterization of Azo Compounds

This study included the design and synthesis of analogues of 8-hydroxyquinoline *azo* compounds, bearing benzene with different substituents (-NO₂, -COOH, -COCH₃). The *azo* compounds were synthesised as previously described in literature [24]. The primary aromatic amine compounds (2 mmol) were independently reacted with NaNO₂ (1 M, 20 mL) in the presence of HCl (2 M, 20 mL, 36 % w/v) at a temperature range of 0-5 °C with the help of an ice bath to achieve diazotization. The clear diazonium solutions were confirmed by the presence of an instantaneous blue color on testing with starch iodide paste or paper. The diazonium compounds were then coupled with 8-hydroxyquinoline in the presence of NaOH (2 M, 200 mL, 98 %) at a temperature range of 0-5 °C in an ice bath while stirring to achieve coupling. The precipitate of the coupled products was filtered by suction and dried, washed, and recrystallized from hot ethanol to give coloured solids **4a-e**, with yields of 60-92 % (**Figure 1**).

Figure 1: General scheme for the synthesis of the azo compounds **4a-e**; **4a** (X=*o*-NO₂), **4b** (X= *m*NO₂), **4c** (X=*p*-NO₂), **4d** (X= *p*-COCH₃), **4e** (X=*p*-COOH): *o*, *m* and *p* represent ortho, meta, and para substitution respectively.

2.5 In silico Pharmacokinetic and Toxicity studies

Computer-aided analysis of the pharmacokinetics and toxicity parameters of the compounds was performed using admetSAR (<http://lmm.d.ecust.edu.cn/admetSAR2/>), an open-access online software, to analyze the Absorption, Distribution, Metabolism, Excretion, and Toxicity (ADMET) properties. The results were further validated with ADMETlab [25], another open-access online software for pharmacokinetic predictions. The parameters for drug-likeness measured included molecular weight, the number of hydrogen bond acceptors (HBA) and donors (HBD), topological polar surface area

(TPSA), and partition coefficient (cLogP). Absorption was calculated as: Percentage (%) Abs = 109 – (0.345 × TPSA) [26]. Toxicity prediction focused on carcinogenicity, Ames mutagenicity, hepatotoxicity, and acute toxicity dose levels.

2.5 Antimicrobial Activity of Synthesised Azo Compounds

2.5.1 Preparation of the Standard 96-Well Plates

A stock concentration of the compounds was serially diluted using dimethyl sulfoxide (DMSO) in a polymerase chain reaction (PCR) half-skirted 96-well plate to give a concentration range 500 – 0.5 µg/mL. DMSO was used at a final concentration of < 1 %. A volume of 2 µL of the compounds was transferred into their corresponding wells in a standard 96-well plate, and the 200 µL of melted agar dispensed into each well with shaking to mix thoroughly. The plates were left undisturbed to solidify [27].

The bacterial suspension (2 µL) of 1×10^6 cfu/mL was spotted on each well. The plates were sealed with transparent foil and wrapped with aluminium foil and incubated at a temperature of 37 °C for 18 to 24 h. Ciprofloxacin and Rifampicin were used as reference drugs for bacteria and *Mycobacterium* respectively. Wells with no drugs were included to serve as growth control. The well containing the lowest concentration of a compound for which no growth was visually observed within the incubation period, was determined as the minimum inhibitory concentration (MIC) of that compound against the microorganisms [27].

2.5.2 Susceptibility of Test Organisms to synthesised compounds

Different concentrations of the *azo* compounds were tested against a panel of Gram-positive bacteria (*Enterococcus faecalis* and *Staphylococcus aureus*), Gram-negative bacteria (*Proteus mirabilis*, *Klebsiella pneumoniae*, *Salmonella typhi*, *Escherichia coli*, and *Pseudomonas aeruginosa*), and an acid-fast bacterium (*Mycobacterium smegmatis*), to determine their MICs using the high-throughput spot culture growth inhibition assay (HT-SPOTi). In the HT-SPOTi assay, molten agar maintained at 55-60 °C was dispensed into 96-well plates to which 2 µL of serially diluted *azo* compounds have been added starting from a stock of 50 mg/mL. The bacterial suspension (2 µL; 1×10^6 cfu/mL) was added to each plate, sealed, and incubated for 18-24 h. The lowest concentration at which bacterial growth was completely inhibited by the compound was observed visually, and the MIC was recorded [28, 29].

2.5.3 Resistant Modulatory Assay

To evaluate the effect of the compounds **4c** and **4e** on selected antibiotics, the combination assay of the compounds with ciprofloxacin and/or rifampicin was evaluated using the HT-SPOTi assay in a 96-well microtitre plate as described in literature with modifications [29, 30]. The compounds were serially diluted in DMSO to include MIC and sub-MIC concentrations. The checkerboard was constructed by adding 1 µL of each of the dilution concentrations to the corresponding well and 1 µL of the MIC of the standard drug was added. The same was done for the standard drug ciprofloxacin and the MIC's of the compounds added. A volume of 200 µL nutrient agar medium or Middlebrook 7H10 agar medium supplemented with 10 % (v/v) Oleic acid Albumin Dextrose Catalase

(OADC) was dispensed into the plates as previously described for the Gram-positive, Gram-negative bacteria and *Mycobacterium* respectively. The plates were then spotted with 2 μ L of bacteria ($\sim 1 \times 10^6$ CFU/mL), sealed, and incubated at 37 °C for 24 h. The Fractional Inhibitory Concentration Indices (FICI) values were calculated using the formula:

$$\text{FICI} = \frac{\text{MIC}_A \text{ in the presence of B}}{\text{MIC}_A} + \frac{\text{MIC}_B \text{ in the presence of A}}{\text{MIC}_B}$$

The combining effect of the compounds in with ciprofloxacin or rifampicin against the pathogens was interpreted as follows: **Synergy, FICI \leq 0.5; Indifference, $0.5 < \text{FICI} < 4.0$; and antagonism, FICI \geq 4.0.**

2.5.4 Biofilm Growth and Biofilm Inhibition Assay

A colorimetric microplate-based assay modified from Cheng *et al.*, 2016 [31], was used to screen the most active compounds (**4c** and **4e**) for biofilm inhibitory activity against *Pseudomonas aeruginosa*, *Staphylococcus aureus*, and *Mycobacterium smegmatis*. *Pseudomonas aeruginosa* and *Staphylococcus aureus* were cultured on Mueller Hinton agar and sub-cultured in Tryptic Soy Broth (TSB), while Middlebrook 7H10 agar media supplemented with 10 % OADC was used to culture *M. smegmatis* and subsequently sub-cultured in TSB. An overnight culture of the micro-organisms was inoculated in 5 mL TSB and incubated at 37 °C for 24 h with shaking at 120 rpm. The cultures were diluted in TSB (supplemented with additional glucose to a final concentration of 1 %) to give $\sim 1 \times 10^6$ cfu/mL (determined by OD₆₀₀). Two-fold serial dilutions of the compounds were done with TSB to give sub-

inhibitory concentrations. The compounds (10 µL) were transferred into a 96-well tissue cultured plate and mixed with TSB supplemented with glucose to give a final concentration of ½ MIC, ¼ MIC, 1/8 MIC, and 1/16 MIC. The wells containing only the inocula were included to serve as growth control whiles Ciprofloxacin and Rifampicin (for *M. smegmatis*) served as drug control. Sterile TSB was added as an additional control to ensure that there was no contamination of the media during the experiment. The plates were incubated at 37 °C for 24 h without shaking to allow cell attachment and biofilm development. Following incubation, the planktonic cells were gently aspirated, and the wells were washed with phosphate buffer saline (PBS, pH 7.2) twice. After rinsing, the biofilm was fixed by incubating for 20 min at 37 °C and staining with 200 µL of 0.1 % (w/v) crystal violet for 10 minutes at room temperature. The excess stain was removed by washing with distilled water and left to air dry. Subsequently, the stain was solubilized with 125 µL of 95 % ethanol for 15 minutes. The optical density of each well was measured at 600 nm (OD₆₀₀) using an automated plate reader (Biotek Synergy H1 Hybrid MultiMode Reader: 271230). The bioassay was performed in triplicate for validation. The results were expressed as percentage inhibition:

$$\text{Percentage Biofilm Inhibition (\%)} = \left(\frac{\text{Control OD}_{600} - \text{Test OD}_{600}}{\text{Control OD}_{600}} \right) \times 100\%$$

NOTE: It takes considerably more time for the visible growth of *Mycobacterium smegmatis* (3-4 days) than other ESKAPE strains. Therefore, you might like to write about the observation of growth *M. smegmatis* in a separate sentence.

2.6 Statistical Analysis

The data from the study were analyzed using GraphPad Prism (Version 8.01, GraphPad Software Inc., USA). The data were described using descriptive statistics and tested inferentially using One-Way analysis of variance (ANOVA) with the Neuman-Keuls post-test. The levels of significance were set at $p < 0.05$ in all scenarios.

3.0 RESULTS AND DISCUSSION

3.1 Characterization of synthesised Azo Compounds

The synthesis of the library of azo dyes (**4a-e**) (**Table 1; Figure 1**) was performed according to methods in the literature. The compounds with NO₂, COCH₃ and COOH substituents were chosen because of their potential antimicrobial activities in studies as reported by works from in literature [32] and [33]. The compounds were obtained in good yields and high purity confirmed by TLC, melting point, and spectroscopic methods. The treatment of 8-hydroxyquinoline (**3**) with various primary aromatic amines (**1a-e**) resulted in the formation of reactive diazonium intermediates (**2a-e**) which were coupled with 8-hydroxyquinoline (**3**) to produce *azo* quinolin-8-ol derivatives. The compounds, **4a-e**, known and reported in literature were confirmed based on IR, UV-Vis, and ¹H NMR spectroscopic data [34]. For instance, the IR spectrum of **4c** showed vibrational bands for OH and N=N at 3088 and 1447 cm⁻¹ respectively. The UV-Vis absorption spectrum of 370 nm confirmed the presence of extended chromophores after molecular hybridization. The sharp uncorrected melting points confirmed the purity of the compounds. The visible colours of the compounds were due to the presence of extended conjugation, which

increases the wavelength of absorption. However, the different colours suggested the presence of varying substituents and their positions on the chromophore system (**Table 1**). This was confirmed by their UV-Vis absorption spectra (**Figure SM1**) and their respective electron transitions (**Table SM1**) [34].

Table 1: Physical properties of the azo compounds.

Compound	R	% yield	Melting points (°C)	Colour
4a	<i>o</i> -nitro	70	218-221	Orange
4b	<i>m</i> -nitro	78	224-227	Orange
4c	<i>p</i> -nitro	85	130-132	Dark brown
4d	<i>p</i> -COCH ₃	60	214-217	Brick red
4e	<i>p</i> -COOH	92	290-293	Dark brown

The template below represents the structural scaffold for the synthesis showing the varying substituents (**Figure 2**).

Figure 2: Scaffold design for 8-hydroxyquinoline *azo* compounds **4a-**

3.1.1 5-(2-nitrophenyl) diazenylquinolin-8-ol (**4a**)

According to the general procedure, *o*-nitroaniline (1.04 g) was reacted with NaNO₂ (1 M, 20 mL,) in the presence of HCl (2 M, 20 mL, 36%) to afford the *title compound* (70 %) as an orange solid after purification (R_f 0.70; EtOAc: MeOH (9:1); Mpt: 218-221 °C; UV-Vis/ nm: 245 and 405; IR; $\nu_{\max}/\text{cm}^{-1}$:3217 (O-H), 1453 and 1433 (N=N), 1340 (C-N stretch).

3.1.2 5-(3-nitrophenyl) diazenylquinolin-8-ol (**4b**)

According to the general procedure, *m*-nitroaniline (1.04 g) was reacted with NaNO₂ (1 M, 20 mL,) in the presence of HCl (2 M, 20 mL, 36 %) to afford the *title compound* (78 %) as an orange solid after purification (R_f 0.73; EtOAc: MeOH (9:1); Mpt: 224-227 °C; UV-Vis/ nm: 245 and 405, IR: $\nu_{\max}/\text{cm}^{-1}$: 3078 (O-H), 1426 and 1404 (N=N), 1348 (C-N stretch).

3.1.3 5-(4-nitrophenyl) diazenyl quinolin-8-ol (4c)

According to the general procedure, *p*-nitroaniline (1.04 g) was reacted with NaNO₂ (1 M, 20 mL) in the presence of HCl (2 M, 20 mL, 36 %) to afford the *title compound* (85 %) as a dark brown solid after purification (R_f 0.76; EtOAc: MeOH (9:1); Mpt: 130-132 °C; UV-Vis/ nm: 255, 275 and 370; IR: $\nu_{\max}/\text{cm}^{-1}$: 3088 (O-H), 1506 and 1447 (N=N), 1232 (C-N stretch).

3.1.4 1-(4-(8-hydroxyquinolin-5-yl) diazenyl) phenyl ethan-1-one (4d)

According to the general procedure, *p*-aminoacetophenone (1.04 g) was reacted with NaNO₂ (1 M, 20 mL,) in the presence of HCl (2 M, 20 mL, 36 %) to afford the *title compound* (60 %) as a brick red solid after purification (R_f 0.65; EtOAc: MeOH (9:1); Mpt: 214-217 °C; UV-Vis/ nm: 250 and 440, IR $\nu_{\max}/\text{cm}^{-1}$: 3080 (O-H), 1554 (N=N), 1357 (C-N stretch).

3.1.5 4-(8-hydroxyquinolin-5-diazenyl) benzoic acid (4e)

According to the general procedure, *p*-aminobenzoic acid (1.04 g) was reacted with NaNO₂ (1 M, 20 mL,) in the presence of HCl (2 M, 20 mL, 36 %) to afford the *title compound* (92 %) as a dark brown solid after purification (R_f 0.80; EtOAc: MeOH (9:1); Mpt: 290-295 °C; UV-Vis/ nm: 250 and 410, IR $\nu_{\max}/\text{cm}^{-1}$: 3066 (O-H), 1581 and 1545 (N=N), 1372 (C-N stretch).

3.2 In Silico Pharmacokinetic and Toxicity Studies

The determination of the pharmacokinetic and toxicity properties of compounds is of great importance in the drug development process, as it has been shown that approximately 40 % of drug candidates fail at the clinical trial stages due to poor absorption, distribution, metabolism, and excretion (ADME) profiles [35]. Therefore, assessing the pharmacokinetics and toxicity properties of molecules in the early stages of drug discovery considerably reduces the risk of late-stage attrition by detecting early problematic properties and focusing on lead optimization efforts to enhancing the desired ones. With this in mind, *in silico* analysis of the 8-hydroxyquinoline *azo* dyes was performed for the evaluation of their ADME properties. The outcomes from the *in-silico* modelling of the synthesised compounds are summarized in **Table 2** and **Table SM3**.

Table 2: In silico physicochemical and pharmacokinetic parameters of synthesised compounds

Physicochemical parameters

Compound	Molecular weight	cLogP	H-bond Donor	H-bond Acceptor	TPSA (140 Å ²)	Rotatable Bonds	% ABS
4a	294.27	4.26	1	6	100.98	3	74.16
4b	294.27	4.26	1	6	100.98	3	74.16
4c	294.27	4.26	1	6	100.98	3	74.16
4d	291.31	4.56	1	5	74.91	3	83.16
4e	293.28	4.05	2	5	95.14	3	76.18

cLog P: Calculated lipophilicity, H-bond Donor: Number of hydrogen bond donors, H-bond Acceptor: Number of hydrogen bond acceptors, TPSA: Polar surface area (Å²), Violation: Number of violations from Lipinski's rule of five, %ABS: Absorption percentage.

The compounds demonstrated good absorption; with the most active compound(s) recording 74.16% (4c) and 76.18 % (4e) absorption (**Table 2**). According to Lipinski's rule-of-5, orally active drugs should show no more than one violation of the following four criteria: molecular weight ≤ 500 , logP (lipophilicity) ≤ 5 , number of hydrogen bond donors ≤ 5 , and number of hydrogen bond acceptors ≤ 10 [36]. None of the compounds violated Lipinski's rule and therefore have the potential to be developed into oral pharmaceutical drugs. TPSA was used to predict the cell permeability and transport properties of compounds and those with TPSA $\leq 140 \text{ \AA}^2$ were predicted to possess good oral bioavailability (**Table 2**). The compounds displayed TPSA values ranging between 74.91 to 100.98 \AA^2 , indicating they had good cell permeabilities and therefore good oral bioavailabilities [37]. The synthesised compounds were predicted to be mildly toxic exhibiting no carcinogenicity but were hepatotoxic and mutagenic (**Table SM3**). They also showed no tendencies to interfere with the cardiac conduction system and were placed in category III of acute oral drugs with LD₅₀ between 500 – 5 000 mg/kg. Further optimization could therefore focus on improving their toxicity profiles.

3.3 Antimicrobial Activity of Synthesised Azo Compounds

3.3.1 Effect of the azo compounds on the test organisms

The MICs of the compounds following the HT-SPOTi assay are shown in **Table 3**. Seven of the pathogens showed susceptibility to the test compounds with only *Salmonella typhi* showing complete resistance to all the five test agents. Among the pathogens tested, *Mycobacterium* was the most resistant, with little susceptibility to the synthesised compounds employed. *Pseudomonas aeruginosa* and *Staphylococcus aureus* possessed least resistance towards the test agents, followed by *Proteus mirabilis*, *Escherichia coli*, *Klebsiella pneumoniae*, and *Enterococcus faecalis*.

Table 3: Antimicrobial activity of the synthesised azo compounds

	<i>Pseudomonas aeruginosa</i>	<i>Staphylococcus aureus</i>	<i>Proteus mirabilis</i>	<i>Escherichia Coli</i>	<i>Klebsiella pneumoniae</i>	<i>Salmonella typhi</i>	<i>Enterococcus faecalis</i>	<i>M. smegmatis</i>
4a	7.8	3.9	15.6	62.5	500	>500	>500	>500
4b	15.6	15.6	15.6	62.5	250	>500	>500	>500
4c	125	15.6	15.6	62.5	250	>500	>500	500
4d	31.2	62.5	31.2	125	>500	>500	>500	>500

4e	7.8	3.9	7.8	125	500	>500	500	500	
CPR	0.9	0.07	≤ 0.5	0.15	≤ 0.5	15.6	≤ 0.5		Minimum

inhibitory concentrations (µg/mL)

Key: CPR-Ciprofloxacin; RPN: Rifampicin; NA: not applicable

3.3.2 Structure-Activity Relationship (SAR) effect on antimicrobial activity of test compounds

Among the substituents on the primary aromatic amine, it was observed that both the nitro and carboxylic groups recorded the highest antimicrobial activity, followed by the ketone group. The study also revealed both the nitro and carboxylic substituents to be active against *Mycobacterium smegmatis* mc² 155. The structural moieties of the

test agents responsible for the antimicrobial activity could be attributed to the varying substituents on the primary aromatic amine as well as their positions on the aromatic ring; be it ortho, meta, or para to the *azo* linkage.

3.3.3 Antimicrobial Resistance Modulation Studies (Combination Assay)

Based on the results obtained from the susceptibility studies, an antimicrobial resistance modulatory activity was carried out using the combination assay for the two most active test compounds (4c and 4e) against the two most susceptible pathogens, *Staphylococcus aureus*, and *Pseudomonas aeruginosa*, as well as *Mycobacterium smegmatis*, the most resistant pathogen, to investigate their synergistic or antagonistic effects. The results of the modulatory studies are shown in **Table SM4** and **Table SM2**. It was observed that 4c and 4e modulated the antimicrobial activity of ciprofloxacin against *Pseudomonas aeruginosa* and *Staphylococcus aureus*. The compounds, 4c and 4e, also modulated the antimicrobial activity of rifampicin against *Mycobacterium smegmatis* (**Table SM2**). The fractional inhibitory concentration index (FICI) of the activity of the test agents were calculated as indicated above (**Table SM3**). A compound is said to be synergistic with the reference drug if its FICI is ≤ 0.5 , indifference with no interaction if FICI is between 0.5 and 4.0 and antagonistic with the reference drug if FICI is above 4.0. As shown in the FICI test results (**Table SM2**), combination of 4c with ciprofloxacin was synergistic against *Pseudomonas aeruginosa*. Combination of 4e with ciprofloxacin was antagonistic against *Staphylococcus aureus*. Both 4c and 4e combination with rifampicin were indifferent against *Mycobacterium smegmatis*, but with high synergistic potential rather than antagonism. Again, combination of 4c with ciprofloxacin against

Staphylococcus aureus and combination of 4e with ciprofloxacin against *Pseudomonas aeruginosa* were also indifferent with high synergistic potential rather than antagonism (**Table SM2**).

3.3.4 Biofilm Inhibition Activity

Microorganisms may develop resistance against antimicrobial agents through the formation of biofilms. Biofilms contribute a significant percentage to microbial infections globally. Therefore, test agents in antimicrobial drug discovery and development may be expected to work to prevent antimicrobial resistance by reducing or inhibiting the formation of these biofilms by the microorganisms [38].

The compounds, 4e and 4c were assessed for their ability to reduce or inhibit formation of bacteria biofilms of *Pseudomonas aeruginosa*, *Staphylococcus aureus*, and *Mycobacterium smegmatis* at 24 h using the sub-inhibitory concentrations 3.9 – 0.49 µg/mL, 1.95 – 0.24 µg/mL, and 250 – 31.25 µg/mL respectively (which corresponded to 1/4, 1/8 and 1/16 MIC by 4c, and 1/2 and 1/16 MIC by 4c) for both compounds. The study showed that both compounds demonstrated biofilm inhibitory effects against the test microorganisms (**Figure 3**). All the concentrations of 4e demonstrated biofilm inhibition against *M. smegmatis* mc² 155, while an inhibitory activity was recorded for 4c at 1/8 and 1/16 MIC. Biofilm inhibition activities of 4e were recorded at 1/4, 1/8 and 1/16 MIC, while that of 4c were at 1/2, 1/4 and 1/18 MIC respectively against *P. aeruginosa* (**Figure 3**). The results further indicated that the antibiofilm activities of 4c and 4e against all the test microorganisms were not

concentration dependent, as increasing concentrations of both compounds did not result in an increase in anti-biofilm effect (**Figure 3**). This shows that the compounds 4c and 4e showed biofilm inhibitory potential at the different concentrations used. The antibacterial activity of 4c and 4e as demonstrated in this study suggests their potential use as scaffolds for further structure optimisation and expansion of the library to improve the antimicrobial profile.




Figure 3. Percentage biofilm inhibition caused by concentrations of 4c and 4e [1/2 MIC: 1.9500 μg/mL, 1/4 MIC: 0.975 μg/mL, 1/8 MIC: 0.4875 μg/mL, and 1/16 MIC: 0.2438 μg/mL] against the biofilm forming (a) *S. aureus*

and (b) *P. aeruginosa*. Ciprofloxacin was employed as the reference drug at 1/2 MIC: 0.0780 µg/mL, 1/4 MIC: 0.0390 µg/mL, 1/8 MIC: 0.0195 µg/mL and 1/16 MIC: 0.00975 µg/mL. (c) *M. smegmatis* mc² 155: 4e and 4c [1/2 MIC: 250 µg/mL, 1/4 MIC: 125 µg/mL, 1/8 MIC: 62.5 µg/mL, and 1/16 MIC: 31.25 µg/mL] against the biofilm forming *M. smegmatis* mc² 155. Rifampicin was employed as the reference drug at 1/2 MIC: 3.9063 µg/mL, 1/4 MIC: 1.9531 µg/mL, 1/8 MIC: 0.9766 µg/mL and 1/16 MIC: 0.4883 µg/mL.

4.0 Conclusions

A library of five (5) azo compounds were synthesised through the diazotisation and coupling pathways. 5-(4-nitrophenyl diazenyl) quinolin-8-ol (4c) and 4-(8-hydroxyquinolin-5-diazenyl) benzoic acid (4e) exhibited better antibacterial and antimycobacterial activities against *Mycobacterium tuberculosis* and two ESKAPE organisms (*Staphylococcus aureus*, and *Pseudomonas aeruginosa*) respectively. Compounds 4c and 4e also exhibited antimicrobial resistance modulatory effects. The resistant modulatory activity and biofilm inhibition potential of

Competing Interests

Authors have declared that they have no known competing financial interests OR non-financial interests OR personal relationships that could have appeared to influence the work reported in this paper

REFERENCES

1. Fair, R. J., & Tor, Y. (2014) Antibiotics and Bacterial Resistance in the 21st Century. *Perspectives in Medicinal Chemistry*. vol. 6, 25–64. doi: [10.4137/PMC.S14459](https://doi.org/10.4137/PMC.S14459)
2. Furuse, Y. (2019) Analysis of research intensity on infectious disease by disease burden reveals which infectious diseases are neglected by researchers, *PNAS Journal*. vol. 116, 478-483. <https://doi.org/10.1073/pnas.1814484116>
3. Coates, A.R., Halls, G., Hu, Y. (2011) Novel classes of antibiotics or more of the same? *British Journal of Pharmacology*. vol. 163, 184–194. <https://doi.org/10.1111/j.1476-5381.2011.01250.x>
4. Wickremasinghe, A. R., Wickremasinghe, R., Herath, H.D.B., & Fernando, S.D. (2017) Should chemoprophylaxis be a main strategy for preventing re-introduction of malaria in highly receptive areas? Sri Lanka a case in point. *Malaria Journal*. vol. 16, 1–6. <https://doi.org/10.1186/s12936-017-1763-6>
5. Soto, S.M. (2013) Role of efflux pumps in the antibiotic resistance of bacteria embedded in a biofilm, *Virulence*. vol. 4, 223–229. doi: [10.4161/viru.23724](https://doi.org/10.4161/viru.23724)
6. Lima, A.D., Chiaradia-delatorre, L.D., Mascarello, A., Andrinéia, K., Oliveira, D., & César, P. (2013) Synthetic organic compounds with potential for bacterial biofilm inhibition , a path for the identification of compounds interfering with quorum sensing. *International Journal of Antimicrobial Agents*. vol. 42, 519–523. <https://doi.org/10.1016/j.ijantimicag.2013.07.006>
7. Santajit, S., & Indrawattana, N. (2016) Mechanisms of Antimicrobial Resistance in ESKAPE Pathogens. *BioMed Research International*. 2016, 1-8. <https://doi.org/10.1155/2016/2475067>

8. Manchanda, V., Sinha, S., & Singh, N. (2010) Multidrug resistant Acinetobacter. *Journal of Global Infectious Diseases*. 2010, 291-304. <https://doi.org/10.4103/0974-777x.68538>.
9. Spampinato, C., Leonardi, D. (2013) Candida infections, causes, targets, and resistance mechanisms: Traditional and alternative antifungal agents. *BioMed Research International*. 2013, 1-13. <https://doi.org/10.1155/2013/204237>.
10. Gordon, S.V., & Parish, T. (2018) Microbe profile: *Mycobacterium tuberculosis*: Humanity's deadly microbial foe. *Microbiology*. vol. 164, 437– 439. doi: [10.1099/mic.0.000601](https://doi.org/10.1099/mic.0.000601)
11. Palomino, J.C., Martin, A. (2014) Drug resistance mechanisms in *Mycobacterium tuberculosis*. *Antibiotics*. vol. 3, 317–340. <https://doi.org/10.3390/antibiotics3030317>
12. Haque, S., Nawrot, D.A., Alakurtti, S., Ghemtio, L., & Yli-kauhaluoma, J. (2014) Screening and Characterisation of Antimicrobial Properties of Semisynthetic Betulin Derivatives. *PLOS ONE*. vol. 9, e102696. doi:10.1371/journal.pone.0102696.
13. Hyde, J., Gorham, C., Brackney, D. E., & Steven, B. (2019). Antibiotic resistant bacteria and commensal fungi are common and conserved in the mosquito microbiome. *PLoS ONE*, 14(8), 1–16. <https://doi.org/10.1371/journal.pone.0218907>
14. Hutchings, M., Truman, A., & Wilkinson, B. (2019) Antibiotics: past, present and future. *Current Opinion in Microbiology*. vol. 51, 72–80. <https://doi.org/10.1016/j.mib.2019.10.008>

15. Domalaon, R., Idowu, T., Zhanel, G.G., & Schweizer, F. (2018) Antibiotic hybrids: The next generation of agents and adjuvants against gram-negative pathogens? *Clinical Microbiology Reviews*. vol. 31, 1–45. <https://doi.org/10.1128/CMR.00077-17>
16. Kyei, S.K., Akaranta, O., & Darko, G. (2020) Synthesis, characterization and antimicrobial activity of peanut skin extract-azo-compounds. *Scientific African*. vol. 8, e00406 <https://doi.org/10.1016/j.sciaf.2020.e00406>
17. Patel, P., & Patel, P.S. (2018) Synthesis, characterization, and antimicrobial activity of heterocyclic azo dye derivatives. *World Scientific News*. vol. 95, 265–272.
18. Shihab, N.L., Intedhar, K.M. (2013) Synthesis of some novel heterocyclic azo dyes for acridine derivatives and evaluation of their antibacterial activities. *Journal of Chemical and Pharmaceutical Research*. vol.5, 345–354.
19. Stanasel, O., & Bota, S. (2018). 2-Amino-1,3,4-thiadiazole as a potential scaffold for promising antimicrobial agents. *Drug design, development and therapy*. vol. 12, 1545–1566. <https://doi.org/10.2147/DDDT.S155958>.
20. Adu, J.K., Amengor, C.D.K., Mohammed, I.N., Amaning-Danquah, C., Owusu-Ansah C., Gbadago, D.D., & Sarpong-Agyapong, J. (2020) Synthesis and *in vitro* Antimicrobial and Anthelmintic Evaluation of Naphtholic and Phenolic Azo Dyes. *Journal of Tropical Medicine*. 2020, 1-8. <https://doi.org/10.1155/2020/4850492>
21. Akram, D., Elhaty, I.A. (2020) Synthesis and Antibacterial Activity of Rhodanine-Based Azo Dyes and their Use as Spectrophotometric Chemosensor for Fe^{3+} Ions. *Chemosensors*. vol. 8, 1-13. <https://doi.org/10.3390/chemosensors8010016>

22. Taboureau, O., Baell, J.B., Fernández-Recio, J., & Villoutreix, B.O. (2012) Established and emerging trends in computational drug discovery in the structural genomics era. *Chemistry and Biology*. vol. 19, 29–41. <https://doi.org/10.1016/j.chembiol.2011.12.007>
23. Sunil, R., Pal, S., & Jayashree, A. (2019) Molecular Hybridization - An Emanating Tool in Drug Design. *Medicinal Chemistry*. vol. 9, 93–95. doi:10.2174/1568026619666190619115735.
24. Albasha, M. (2018) Synthesis, Characterization of New Azo Compounds and Their Biological Evaluation. *International Journal of Academic Scientific Research*. vol. 4, 16-24
25. Dong, J., Wang, N., & Yao, Z. (2018) ADMETlab: a platform for systematic ADMET evaluation based on a comprehensively collected ADMET database. *Journal of Cheminformatics*. vol. 10, 29. <https://doi.org/10.1186/s13321-018-0283-x>
26. Abdullahi, M., & Elijah, S. (2020) In - silico Molecular Docking and ADME / Pharmacokinetic Prediction Studies of Some Novel Carboxamide Derivatives as Anti - tubercular Agents. *Chemistry Africa*. 2020; <https://doi.org/10.1007/s42250-020-00162-3>
27. Adusei, E. B. A., Adosraku, R. K., Oppong-Kyekyeku, J., Amengor, C. D. K., & Jibira, Y. (2019). Resistance Modulation Action, Time-Kill Kinetics Assay, and Inhibition of Biofilm Formation Effects of Plumbagin from *Plumbago zeylanica* Linn. *Journal of Tropical Medicine*, 2019. <https://doi.org/10.1155/2019/1250645>

28. Desai, N.C., Bhatt, N., Somani, H., & Trivedi, A. (2013) Synthesis, antimicrobial and cytotoxic activities of some novel thiazole clubbed 1,3,4-oxadiazoles. *European Journal of Medicinal Chemistry*. vol. 67, 54–59. <https://doi.org/10.1016/j.ejmech.2013.06.029>
29. O'Donnell, G., Poeschl, R., Zimhony, O., Gunaratnam, M., Moreira, J.B.C., Neidle, S., & Evangelopoulos, D. (2009) Bioactive pyridine-N-oxide disulfides from *allium stipitatum*. *Journal of Natural Products*. vol. 72, 360–365. <https://doi.org/10.1021/np800572r>
30. Gibbons, S. (2005) Plants as a source of bacterial resistance modulators and anti-infective agents. *Phytochemistry Reviews*. vol. 4, 63–78. <https://doi.org/10.1007/s11101-005-2494-9>
31. Cheng, H., Xie, Y., Villalobos, L.F., Song, L., Peinemann, K.V., Nunes, S., Hong, P.Y. (2016) Antibiofilm effect enhanced by modification of 1,2,3-triazole and palladium nanoparticles on polysulfone membranes. *Scientific Reports*. vol. 6, 1–12. <https://doi.org/10.1038/srep24289>
32. Shreve, R. N., & Bennet, B.R. (1943) Studies in Azo Dyes. II. Preparation and Bacteriostatic Properties of Azo Derivatives of 8-Quinolinol, *Journal of American Chemical Society*, vol. 65, 2243-2245.
33. Albasha M. (2018) Synthesis, Characterization of New Azo Compounds and Their Biological Evaluation. *International Journal of Academic Scientific Research*. Vol. 4, 16-24
34. Saylam, A., Seferoğlu, Z., & Ertan, N. (2014) Azo-8-hydroxyquinoline dyes: The synthesis, characterizations and 2 determination of tautomeric properties of some new 3 phenyl- and heteroarylazo-8-hydroxyquinolines. *Journal of Molecular Liquids*. vol. 195, 267-276. <http://dx.doi.org/10.1016/j.molliq.2014.02.02>

35. Alavijeh, M.S., & Palmer, A.M. (2004) The pivotal role of drug metabolism and pharmacokinetics in the discovery and development of new medicines. vol.7, 755–763. PMID: 15334309
36. Araujo de Brito M. (2011) Pharmacokinetic study with computational tools in the medicinal chemistry course. Brazilian Journal of Pharmaceutical Sciences. vol. 4, 795-805
37. Whitty, A., Zhong, M., Viarengo, L., Beglov, D., Hall, D.R., & Vajda, S. (2016) Quantifying the chameleonic properties of macrocycles and other high-molecular-weight drugs. Drug Discovery Today. vol. 5, 712-717
38. Rajput, A., Thakur, A., Sharma, S., Kumar, M. (2018) ‘A biofilm: a resource of anti-biofilm agents and their potential implications in targeting antibiotic drug resistance,’ *Nucleic acids Research*. vol 46, 894–900.
<https://doi.org/10.1093/nar/gkx1157>